Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.

Frontiers in immunology - 1 Jan 2026

Akhavan Baylor, Samlowski Wolfram

Abstract excerpt

Simple summary: Combinations of monoclonal antibodies that activate the immune system have been highly effective for treatment of melanoma that has spread (metastasized). Unfortunately, this type of immunotherapy treatment can trigger serious side effects. Thus, it would be valuable to predict patients who are unlikely to benefit from immunotherapy in advance. We evaluated four cancer-related markers to determine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Ipilimumab

Share to Melanoma

Share to Nivolumab

Share to Progression-Free Survival

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41694351
DOI: 10.3389/fimmu.2026.1729883
PMCID: PMC12894002

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.PMID 41694351Read ↗

Evaluation of Prognostic Markers for Progression-Free Survival of Metastatic Melanoma Patients Treated with First-Line Ipilimumab Plus NivolumabSemantic proximity Read ↗

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.Semantic proximity Read ↗

Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.Semantic proximity Read ↗

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.Semantic proximity Read ↗

The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.Semantic proximity Read ↗

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.Semantic proximity Read ↗

Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.Semantic proximity Read ↗

Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series.Semantic proximity Read ↗

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.Semantic proximity Read ↗

PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.Semantic proximity Read ↗

Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase.Semantic proximity Read ↗

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.